Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens

Part of paid clinical trials in Nashville, Tennessee.

Sponsor
Bristol-Myers Squibb
Study ID
NCT07689006
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pomalidomide-containing regimens — DRUG
    Exposure to pomalidomide-containing index regimens, including daratumumab, pomalidomide, and dexamethasone (DPd) and carfilzomib, pomalidomide, and dexamethasone (KPd), administered in routine clinical practice.
  • Non-pomalidomide-containing regimens — DRUG
    Exposure to non-pomalidomide-containing index regimens, including daratumumab, lenalidomide, and dexamethasone (DRd), daratumumab, bortezomib, and dexamethasone (DVd), and daratumumab, carfilzomib, and dexamethasone (DKd), administered in routine clinical practice.

Study Details

This retrospective observational study will use data from the OneOncology United States database to evaluate clinical outcomes in adults with relapsed/refractory multiple myeloma who received pomalidomide-containing or non-pomalidomide-containing treatment as second-line or third-line therapy after prior exposure to lenalidomide and a proteasome inhibitor.

Key Dates

First listed
Jul 7, 2026
Start date
Dec 23, 2024
Status verified
Jun 2026
Primary completion
Mar 28, 2025
Completion
Mar 28, 2025

Study Design

Enrollment
341 participants (actual)

Arms

  • Arm: Pomalidomide-containing regimens
    Participants who initiated daratumumab, pomalidomide, and dexamethasone (DPd) or carfilzomib, pomalidomide, and dexamethasone (KPd) index regimens in the 2L or 3L setting after prior exposure to lenalidomide and a proteasome inhibitor.
  • Arm: Non-pomalidomide-containing regimens
    Participants who initiated daratumumab, lenalidomide, and dexamethasone (DRd), or daratumumab, bortezomib, and dexamethasone (DVd), or daratumumab, carfilzomib, and dexamethasone (DKd) index regimens in the 2L or 3L setting after prior exposure to lenalidomide and a proteasome inhibitor.

Primary Outcome Measure

Progression-Free Survival (PFS) among participants who initiated pomalidomide-containing index regimens [ Time Frame: Up to 6 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
OneOncology NetworkNashvilleTennessee37219-

Find similar trials in Nashville, TN

Nationwide
Multiple myeloma trialsOncology trialsBlood cancer trials
By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
OneOncology Network· Nashville, TN

Related Studies